Stugeron, pills 25mg, 50pcs

Composition

1 tablet contains:

Active ingredients:

cinnarizine – 25 mg.

Auxiliary substances:

colloidal silicon dioxide,

potato starch,

magnesium stearate,

povidone,

talc,

corn starch,

lactose monohydrate.

Pharmacological action

Pharmacodynamics

Selective calcium channel blocker of class IV. Improves cerebral, coronary and peripheral blood circulation; improves microcirculation.

By inhibiting the intake of calcium ions into the smooth muscle cells of blood vessels, it reduces the tone of the smooth muscle membrane of arterioles; reduces their sensitivity to biogenic vasoconstrictor substances ( epinephrine, norepinephrine), bradykinin. Reduces the excitability of the vestibular apparatus. It is characterized by a high tropicity to the vessels of the brain. Improves microcirculation, increasing the deformability of red blood cells and reducing the increased blood viscosity. It has moderate antihistamine activity.

Pharmacokinetics

Suction

After oral use, cmax of cinnarizine in plasma is noted in 1-3 hours.

Distribution

Binding to plasma proteins is 91%.

Metabolism

Cinnarizine is completely metabolized.

Elimination

T 1/2 is 4 h. It is excreted in the form of metabolites: 1/3-by the kidneys,2/3 – through the intestines.

Indications

• Treatment and prevention of violations of cerebral circulation: cerebral atherosclerosis, conditions after stroke, traumatic brain injury, encephalopathy;
• labyrinth disorders (supportive therapy for dizziness, tinnitus, nystagmus, nausea, vomiting);
• prevention of kinetosis;
• migraine prevention;
• treatment and prevention of peripheral circulatory disorders: disease and Raynaud’s syndrome; acrocyanosis, intermittent claudication, trophic disorders, trophic and varicose ulcers, diabetic angiopathy, paresthesia, disturbance of microcirculation;
• in the complex therapy in the following cases: rapid mental fatigue, irritability, low mood, impaired memory and ability to concentrate.

Use during pregnancy and lactation

Despite the fact that the teratogenic effect of Stugeron has not been established in animal studies, the use of the drug during pregnancy is possible only in exceptional cases, when the expected benefit to the mother significantly exceeds the potential risk to the fetus.

It is not known whether cinnarizine is excreted in breast milk, so the use of Stugeron during lactation (breastfeeding) is not recommended.

Contraindications

Hypersensitivity to the drug. Erythematous lupus.

Side effects

From the digestive system: dyspepsia, dry mouth; in some cases – cholestatic jaundice.

From the central nervous system: rarely-headache; in senile patients with prolonged use of Stugeron, extrapyramidal syndromes, depression are possible (in such cases, treatment should be interrupted).

Other: allergic reactions, weight gain, increased sweating; in isolated cases – lupus-like syndrome, lichen planus.

Interaction

With the combined use of Stugeron and ethanol (or ethanol-containing drugs), antihypertensive, nootropic and vasodilating agents, and other drugs that have a depressing effect on the central nervous system (tricyclic antidepressants, sleeping pills, sedatives), their effect is increased.

How to take, course of use and dosage

They are installed individually. The optimal therapeutic dose should be taken gradually. The maximum daily dose is 225 mg (9 tablets).

The drug should be taken after a meal.

Children aged 6-12 years are prescribed half the adult dose.

For disorders of cerebral circulation

Adults are prescribed 25-50 mg 3 times a day.

In case of peripheral circulatory disorders

Assign 50-75 mg 3 times a day.

For labyrinth disorders

Assign 25 mg 3 times a day.

For the prevention of kinetosis

Adults are prescribed 25 mg 30 minutes before travel with repeated intake every 6 hours.

Overdose

Symptoms: vomiting, drowsiness, tremor, hypotension, coma.

Treatment: gastric lavage, use of activated charcoal; conduct symptomatic therapy. There is no specific antidote.

Special instructions

In Parkinson’s disease, Stugeron is prescribed only in exceptional cases, when the expected benefit significantly exceeds the potential risk.

Stugeron, due to the presence of an antihistamine effect, can level out positive reactions during skin diagnostic tests. In this regard, the drug should be discontinued 4 days before the test.

Patients taking the drug are prohibited from drinking alcohol.

Monitoring of laboratory parameters

With prolonged use of Stugeron, monitoring of laboratory blood parameters and liver and kidney function indicators is recommended.

Influence on the ability to drive vehicles and other mechanisms that require increased concentration of attention

Patients taking the drug should exercise caution when engaging in activities that require increased attention and speed of psychomotor reactions.

Form of production

Stugeron tablets are white or almost white in color, round, flat, chamfered, almost odorless, with the inscription “STUGERON” on one side and with a risk for breaking – on the other.

Storage conditions

Store in a dry place protected from light at a temperature of 15° C to 30°C. Keep out of reach of children.

Shelf

life is 5 years.

Active ingredient

Cinnarizine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets